Stockscreener 앱 받기
5.23
4.39%
0.22
Immatics N V 주식(IMTX)의 최신 뉴스
Immatics US opens 100,000-square-foot Stafford cell-therapy manufacturing plant (PHOTOS) - The Business Journals
Guggenheim Capital LLC Takes $101,000 Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Are Immatics N.V (IMTX) shares a good deal now? - uspostnews.com
Immatics Announces Upcoming Oral and Poster Presentation on IMA2 - GuruFocus
Immatics N.V. to Present Updated Data on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Nasdaq
Immatics Announces Upcoming Oral and Poster Presentation on - GlobeNewswire
Breakthrough Melanoma Treatment IMA203 : Phase 1b Results and Phase 3 Progress Coming to ASCO 2025 - Stock Titan
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - Yahoo
Short Interest in Immatics (NASDAQ:IMTX) Declines By 20.7% - Defense World
Immatics N.V (NASDAQ: IMTX): Moving Toward A Higher Share Price - Stocksregister
(IMTX) Long Term Investment Analysis - news.stocktradersdaily.com
Immatics N.V (NASDAQ: IMTX): Can’t Stop The Stock’s Slide? - stocksregister.com
FY2025 EPS Estimates for Immatics Decreased by Analyst - Defense World
Financial Contrast: Novonesis A/S (OTC:NVZMY) and Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Research Analysts Set Expectations for Immatics Q1 Earnings - The AM Reporter
Q1 Earnings Estimate for Immatics Issued By Leerink Partnrs - Defense World
Immatics Reports Strong 2024 Financial Results and Progress - TipRanks
Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView
Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks
Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - Stock Titan
Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World
IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
(IMTX) Trading Report - Stock Traders Daily
Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World
Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex
Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World
(IMTX) Trading Signals - Stock Traders Daily
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat
abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat
New Strong Buy Stocks for February 12th - Yahoo Finance
Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance
Immatics N.V (IMTX): An Important Analyst Insights - Stocks Register
Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News
Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat
Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat
Immatics N.V (IMTX) Volatility Hits 4.72% – Here Is What You Should Do - Stocks Register
0.47%
2.63%
자본화:
|
볼륨(24시간):